Biotech · Private company
REMD Biotherapeutics, Inc.
Track this companyFree. Adds REMD Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- REMD-477Phase 2 · Type1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- VolagidemabPhase 1 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With VolagidemabPHASE1 · COMPLETED · started Feb 15, 2024ClinicalTrials.gov NCT06272695 · fetched Nov 12, 2026
- Effects of GRA in Patients With Type 1PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 31, 2021ClinicalTrials.gov NCT04779645 · fetched Nov 12, 2026
- Combination GRA and SGLT-2i Treatment in Type 1 DiabetesPHASE1_PHASE2 · COMPLETED · started Feb 22, 2021ClinicalTrials.gov NCT04545411 · fetched Nov 12, 2026
- Metabolic Pathways of GRA in Patients With Type 1 DiabetesPHASE1_PHASE2 · COMPLETED · started Jul 1, 2019ClinicalTrials.gov NCT03919617 · fetched Nov 12, 2026
- Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusPHASE2 · COMPLETED · started Sep 19, 2017ClinicalTrials.gov NCT03117998 · fetched Nov 12, 2026